Kurt G. Pike

2.1k total citations
37 papers, 863 citations indexed

About

Kurt G. Pike is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, Kurt G. Pike has authored 37 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 15 papers in Organic Chemistry and 6 papers in Surgery. Recurrent topics in Kurt G. Pike's work include DNA Repair Mechanisms (6 papers), Pancreatic function and diabetes (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Kurt G. Pike is often cited by papers focused on DNA Repair Mechanisms (6 papers), Pancreatic function and diabetes (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Kurt G. Pike collaborates with scholars based in United Kingdom, United States and Singapore. Kurt G. Pike's co-authors include Martin Pass, Darren McKerrecher, Craig Johnstone, Keith Menear, Karine Malagu, Niall M.B. Martin, Sylvie Gomez, Linette Ruston, Marc Hummersone and Bernard Barlaam and has published in prestigious journals such as Cancer Research, Chemical Communications and Journal of Medicinal Chemistry.

In The Last Decade

Kurt G. Pike

36 papers receiving 845 citations

Peers

Countries citing papers authored by Kurt G. Pike

Since Specialization

Citations

This map shows the geographic impact of Kurt G. Pike's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt G. Pike with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt G. Pike more than expected).

Fields of papers citing papers by Kurt G. Pike

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt G. Pike. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt G. Pike. The network helps show where Kurt G. Pike may publish in the future.

Co-authorship network of co-authors of Kurt G. Pike

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt G. Pike. A scholar is included among the top collaborators of Kurt G. Pike based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt G. Pike. Kurt G. Pike is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase 2025 ·Drug Metabolism and Disposition ·Nicola Colclough, (unknown), Scott E. Martin, Martin Wild, Venkatesh Pilla Reddy, Eva M. Lenz, (unknown), Joanne Wilson, Chunling Fan, Julia M. Potter, (unknown), Christina Chan, Jennie Roberts, (unknown), Petar Pop-Damkov, (unknown), Barry Jones, Thomas A. Hunt, Kurt G. Pike, Dermot F. McGinnity	1
2	Identification and optimization of a novel series of selective PIP5K inhibitors 2021 ·Bioorganic & Medicinal Chemistry ·David Andrews, (unknown), Sabina Cosulich, Nullin Divecha, Paul Faulder, Vikki Flemington, (unknown), Jason G. Kettle, (unknown), (unknown), Kurt G. Pike, Bryan Roberts, Rachel Rowlinson, James M. Smith, Martin L. Stockley, Martin E. Swarbrick, Iris Treinies, Michael J. Waring	7
3	Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase 2021 ·Bioorganic & Medicinal Chemistry Letters ·Daniel H. O’Donovan, (unknown), Martin J. Packer, Ryan Greenwood, Kurt G. Pike, Sameer Kawatkar, Andrew Bloecher, James Robinson, Jon Read, Erin Code, Jessie Hao-Ru Hsu, Minhui Shen, (unknown), Peter Barton, Shaun Fillery, Beth Williamson, Philip B. Rawlins, Sharan K. Bagal	11
4	Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors 2018 ·ACS Medicinal Chemistry Letters ·Bernard Barlaam, Elaine Cadogan, Andrew D. Campbell, Nicola Colclough, Allan Dishington, Stephen T. Durant, Kristin Goldberg, Lorraine Hassall, Gareth Hughes, Philip A. MacFaul, Thomas M. McGuire, Martin Pass, Anil S. Patel, Stuart E. Pearson, Jens Petersen, Kurt G. Pike, Graeme R. Robb, Natalie Stratton, (unknown), (unknown)	19
5	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase 2016 ·Journal of Medicinal Chemistry ·Sébastien L. Degorce, Bernard Barlaam, Elaine Cadogan, Allan Dishington, Richard Ducray, (unknown), Lorraine Hassall, (unknown), Alan Lau, Thomas M. McGuire, Thorsten Nowak, Gilles Ouvry, Kurt G. Pike, Andrew Thomason	55
6	Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL -rearranged AML 2016 ·Science Signaling ·(unknown), Amanda Day, Matilde Murga, Vanesa Lafarga, (unknown), Anthony Tubbs, Hua-Tang Chen, (unknown), (unknown), Avinash Bhandoola, Kurt G. Pike, Bernard Barlaam, Elaine Cadogan, Xi Wang, Andrew J. Pierce, (unknown), Scott A. Armstrong, André Nussenzweig, Óscar Fernández-Capetillo	46
7	Abstract 4859: Identifying high quality, potent and selective inhibitors of ATM kinase: Discovery of AZD0156 2016 ·Cancer Research ·Kurt G. Pike	1
8	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules 2015 ·Molecular Cancer Therapeutics ·Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich	103
9	Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014 2013 ·Bioorganic & Medicinal Chemistry Letters ·Kurt G. Pike, Karine Malagu, Marc Hummersone, Keith Menear, (unknown), Sylvie Gomez, Niall M.B. Martin, Linette Ruston, (unknown), Martin Pass	166
10	A Concise Total Synthesis of Deoxyschizandrin and Exploration of Its Antiproliferative Effects and those of Structurally Related Derivatives 2012 ·Chemistry - A European Journal ·Shaojun Zheng, (unknown), Luca Laraia, Warren R. J. D. Galloway, Kurt G. Pike, Wenjun Wu, David R. Spring	9
11	Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor 2012 ·Bioorganic & Medicinal Chemistry Letters ·M. Raymond V. Finlay, David Buttar, Susan E. Critchlow, Allan Dishington, Shaun Fillery, Eric F. Fisher, (unknown), M. A. Graham, Trevor Johnson, Gillian M. Lamont, Simon P. Mutton, Paula Perkins, Kurt G. Pike, Anthony M. Slater	27
12	Synthesis of 3-Substituted 2-Aminopyridines via Displacement of 3-Fluoro-2-nitropyridine 2012 ·Synlett ·Jonathan Eden, David Perkins, Janet D. Culshaw, (unknown), Barry R. Hayter, Kurt G. Pike	0
13	Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092 2011 ·MedChemComm ·Michael J. Waring, Craig Johnstone, Darren McKerrecher, Kurt G. Pike, Graeme R. Robb	21
14	Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life 2011 ·Bioorganic & Medicinal Chemistry Letters ·Kurt G. Pike, Joanne V. Allen, Peter W. R. Caulkett, David S. Clarke, Craig S. Donald, (unknown), (unknown), Craig Johnstone, Darren McKerrecher, (unknown), (unknown), (unknown)	26
15	Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR 2009 ·Bioorganic & Medicinal Chemistry Letters ·Keith Menear, Sylvie Gomez, Karine Malagu, C. L. Bailey, (unknown), Xiaoling Cockcroft, (unknown), (unknown), Armelle Le Gall, (unknown), (unknown), (unknown), (unknown), (unknown), Ian Hickson, Niall M.B. Martin, Graeme C.M. Smith, Kurt G. Pike	51
16	Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats 2006 ·British Journal of Pharmacology ·(unknown), (unknown), (unknown), Darren McKerrecher, Craig Johnstone, Kurt G. Pike, Petter Holme, (unknown), Débora Gil, Matthew P. Coghlan, Brendan Leighton	67
17	Design of a potent, soluble glucokinase activator with excellent in vivo efficacy 2006 ·Bioorganic & Medicinal Chemistry Letters ·Darren McKerrecher, Joanne V. Allen, Peter W. R. Caulkett, Craig S. Donald, (unknown), (unknown), (unknown), Craig Johnstone, Clifford D. Jones, Kurt G. Pike, (unknown), (unknown)	71
18	A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis 2004 ·Bioorganic & Medicinal Chemistry Letters ·Dearg S. Brown, Andrew Belfield, George R. Brown, Douglas S. Campbell, Alan J. Foubister, (unknown), Kurt G. Pike, (unknown), Stuart L. Wells	17
19	Aminative rearrangement of 2-alkoxy-3,4-dihydro-2H-pyrans: a novel stereocontrolled route to substituted pyrrolidinesElectronic supplementary information (ESI) available: experimental details and characterisation data for all new compounds. See http://www.rsc.org/suppdata/cc/b3/b316554j/ 2004 ·Chemical Communications ·Alan Armstrong, Graham R. Cumming, Kurt G. Pike	9
20	Radical cyclisations of methylenecyclopropyl azetidinones—synthesis of novel tricyclic β-lactams 2000 ·Tetrahedron Letters ·(unknown), Kurt G. Pike, A.R.J. Genge, Mike Anson, John Kitteringham, Jeremy Kilburn	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact